VBI Vaccines, Inc.
(NASDAQ : VBIV)

( )
VBIV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.61%93.101.3%$988.29m
BIIBBiogen Inc.
-2.52%224.401.3%$650.41m
AMGNAmgen Inc.
-0.81%178.301.3%$468.17m
GILDGilead Sciences, Inc.
-0.38%62.800.9%$434.85m
ILMNIllumina, Inc.
-2.34%314.523.5%$280.91m
REGNRegeneron Pharmaceuticals, Inc.
-1.07%340.462.6%$279.54m
VRTXVertex Pharmaceuticals Incorporated
-1.59%172.581.9%$238.29m
ALXNAlexion Pharmaceuticals, Inc.
-1.72%130.092.0%$169.34m
EXASExact Sciences Corporation
1.27%95.1325.3%$167.52m
AAgilent Technologies, Inc.
0.30%75.791.6%$145.62m
SRPTSarepta Therapeutics, Inc.
0.06%118.1614.7%$133.09m
ONCESpark Therapeutics, Inc.
0.06%110.6711.2%$117.72m
INCYIncyte Corporation
-2.51%73.522.5%$96.42m
IONSIonis Pharmaceuticals, Inc.
-2.23%73.338.3%$95.85m
BMRNBioMarin Pharmaceutical Inc.
-0.59%85.494.3%$92.14m

Company Profile

VBI Vaccines, Inc. operates as a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology. The firm offers offers development programs, HBV Therapeutic, Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Prophylaxis. Its eVLP Platform technology allows for the development of enveloped virus-like particle eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.